Last €79.79 EUR
Change Today +1.12 / 1.42%
Volume 17.0
XP2 On Other Exchanges
Symbol
Exchange
Berlin
NASDAQ GS
As of 11:35 AM 04/24/14 All times are local (Market data is delayed by at least 15 minutes).

salix pharmaceuticals ltd (XP2) Snapshot

Open
€79.61
Previous Close
€78.67
Day High
€79.79
Day Low
€78.94
52 Week High
02/28/14 - €86.02
52 Week Low
04/24/13 - €37.88
Market Cap
5.1B
Average Volume 10 Days
134.5
EPS TTM
--
Shares Outstanding
63.3M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for SALIX PHARMACEUTICALS LTD (XP2)

salix pharmaceuticals ltd (XP2) Related Businessweek News

No Related Businessweek News Found

salix pharmaceuticals ltd (XP2) Details

Salix Pharmaceuticals, Ltd. acquires, develops, and commercializes prescription drugs and medical devices to treat various gastrointestinal diseases in the United States. The company provides XIFAXAN tablets to treat overt hepatic encephalopathy, and patients with travelers’ diarrhea; APRISO too maintain remission of ulcerative colitis (UC); MOVIPREP and OSMOPREP for cleansing of the colon as a preparation for colonoscopy in adults; RELISTOR for the treatment of opioid-induced constipation (OIC) in patients with advanced illness; SOLESTA to treat fecal incontinence; and DEFLUX to treat vesicoureteral reflux. It also offers FULYZAQ for the symptomatic relief of non-infectious diarrhea in adult patients with HIV/AIDS on anti-retroviral therapy; GIAZO, COLAZAL, and UCERIS to treat mildly to moderately active UC; and METOZOLV ODT for the treatment of refractory gastroesophageal reflux disease (GERD) that fails to respond to conventional therapy. Its products also comprise AZASAN azathioprine tablets, which are used as adjunct to prevent rejection in renal homotransplantations and to reduce signs and symptoms of severe active rheumatoid arthritis; ANUSOL-HC and PROCTOCORT for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses; and PEPCID for the short-term treatment of GERD, active duodenal ulcer, active benign gastric ulcer, erosive esophagitis due to GERD, and peptic ulcer diseases. In addition, the company provides DIURIL to treat hypertension and also as adjunctive therapy; ZEGERID for the treatment of upper gastrointestinal conditions; GLUMETZA and CYCLOSET to enhance glycemic control in adults with type 2 diabetes mellitus; and FENOGLIDE to treat lipoprotein-cholesterol, total cholesterol, triglycerides, and apolipoprotein B, as well as hypertriglyceridemia. It has strategic collaboration with RedHill Biopharma Ltd. Salix Pharmaceuticals, Ltd. was founded in 1989 and is headquartered in Raleigh, North Carolina.

555 Employees
Last Reported Date: 02/28/14
Founded in 1989

salix pharmaceuticals ltd (XP2) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $834.1K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $470.1K
Chief Development Officer, Chief Medical Offi...
Total Annual Compensation: $448.5K
Executive Vice President of Business Developm...
Total Annual Compensation: $420.2K
Compensation as of Fiscal Year 2012.

salix pharmaceuticals ltd (XP2) Key Developments

Progenics Pharmaceuticals, Inc. and Salix Pharmaceuticals, Ltd. Announce Acceptance of European Medicines Agency for Review Salix's Submission for a Variation of the Existing Marketing Authorization for RELISTOR Subcutaneous Injection

Salix Pharmaceuticals Ltd. and Progenics Pharmaceuticals Inc. announced that the submission to the European Medicines Agency of RELISTOR (methylnaltrexone bromide) Subcutaneous Injection for the treatment of opioid-induced constipation (OIC) in adult patients with chronic non-cancer pain, has been accepted for review. If approved, this will add to the current marketing authorization in the European Union (EU), which allows for the use of RELISTOR in advanced illness patients. The marketing of RELISTOR for the treatment of OIC in advanced illness patients was approved in the European Union in 2008, and is currently approved in more than 50 countries. RELISTOR remains the only single agent product approved for the treatment of OIC in the EU. If approved, it is anticipated that RELISTOR will be immediately available to this newly expanded population of patients in the EU using opioids to control chronic pain.

Salix Pharmaceuticals Ltd. and Progenics Pharmaceuticals, Inc. Announce the Acceptance of Submission to Expand the Use of RELISTOR in Chronic Non-Cancer Pain by the European Medicines Agency

Salix Pharmaceuticals Ltd. and Progenics Pharmaceuticals, Inc. announced that the submission to the European Medicines Agency (EMA) of RELISTOR(methylnaltrexone bromide) Subcutaneous Injection for the treatment of opioid-induced constipation (OIC) in adult patients with chronic non-cancer pain, has been accepted for review. If approved, this will add to the current marketing authorization in the European Union (EU), which allows for the use of RELISTOR in advanced illness patients. The marketing of RELISTOR for the treatment of OIC in advanced illness patients was approved in the European Union in 2008, and is currently approved in more than 50 countries. RELISTOR remains the only single agent product approved for the treatment of OIC in the EU. If approved, it is anticipated that RELISTOR will be immediately available to this newly expanded population of patients in the EU using opioids to control chronic pain.

Furiex Puts Itself On The Block

Furiex Pharmaceuticals, Inc. (NasdaqGS:FURX) has reportedly hired Bank of America Corp to find a buyer. Bloomberg reported that Salix Pharmaceuticals Ltd. (NasdaqGS:SLXP), Actavis plc (NYSE:ACT) and Takeda Pharmaceutical Company Limited (TSE:4502) to be potential buyers for Furiex. Tony Plohoros, representative for Furiex, declined to comment. G. Michael Freeman, spokesman for Salix, said the company had no comment when asked if it was considering an acquisition of Furiex. Representatives for Actavis and Takeda declined to comment when asked if they were considering an acquisition of Furiex.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
XP2:GR €79.79 EUR +1.12

XP2 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Almirall SA €11.43 EUR +0.11
Cubist Pharmaceuticals Inc $66.58 USD +0.20
Recordati SpA €12.70 EUR +0.26
Santen Pharmaceutical Co Ltd ¥4,495 JPY -85.00
Synergy Health PLC 1,245 GBp -2.00
View Industry Companies
 

Industry Analysis

XP2

Industry Average

Valuation XP2 Industry Range
Price/Earnings 50.5x
Price/Sales 7.4x
Price/Book 9.3x
Price/Cash Flow 37.1x
TEV/Sales 4.5x
 | 

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SALIX PHARMACEUTICALS LTD, please visit www.salix.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.